New restrictions in China are slowing a clinical-trial route that had become an important engine for rare-disease development, according to a STAT report focused on investigator-initiated trials, or IITs.
The reported change follows deaths, news reports and new government rules that disrupted plans for additional genetic-treatment studies. For developers and patient groups, the significance goes beyond a single foundation or family: the tightening appears to be constraining a system that had allowed some programs to reach human testing faster and more cheaply than in the U.S.
The policy shift
STAT reported from Shanghai that Juan Huang and the Hope for Rare Foundation were pursuing IITs, a Chinese regulatory pathway that allowed investigators to start clinical trials without sign-off from central regulators. Huang said the government has become "very strict" after this summer’s events.
That matters because the IIT structure had supported a different development model. Under the looser rules, Chinese hospitals became more sophisticated centers for diagnosing and treating rare disease, while researchers and foundations could help move genetic treatments into trials at a fraction of the cost in the U.S.
The report said Huang and her foundation had been on track to start two more trials until the policy environment changed. While the source does not quantify how long the slowdown will last, it presents the new rules as a direct interruption to that pipeline.
Why it matters
The effect is not confined to local rare-disease efforts. STAT said the loosened rules had enabled Chinese companies to test drugs in humans faster and cheaper, and that success had prompted U.S. companies either to come to China or to push the Food and Drug Administration to adopt a similar approach.
That makes the clampdown strategically important. If central oversight becomes materially tighter, China may give up part of the speed-and-cost advantage that made IITs attractive for early human studies, especially in areas such as rare genetic disease where small patient populations already complicate trial execution.
The report frames the shift through one family’s experience. Huang’s daughter, Huangxi, lost the ability to stand or walk at 16 months, and it took two years plus a flight to Massachusetts to secure a diagnosis for a genetic disease that had never been identified in China. A decade later, the treatment infrastructure had improved enough to support new trial plans inside China. The new restrictions now threaten that momentum, suggesting that safety concerns and regulatory control are being given more weight than the experimental flexibility that previously accelerated these programs.
